Medtechs Should Not Play Dodgeball With Sales Force Effectiveness
Adoption of sales force effectiveness remains suboptimal across the US medtech industry, which means that companies are missing out on significant annual revenue uplift. But things are changing, and it’s no longer an issue to be delegated: SFE has risen all the way to CEO level.
You may also be interested in...
The previously rumored acquisition was announced on April 28, with the firms touting their extensive synergies in the cardiovascular space.
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.
COVID-19 has forced a rethink in how care should be delivered. Healthcomms Consulting partner Dan Jones says it is an opportunity that must not be squandered.